Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Suarez Arroyo, Ivette J ^a   Rosario Acevedo, Raysa ^a   Aguilar Perez, Alexandra ^a   Clemente, Pedro L ^a   Cubano, Luis A ^a   Serrano, Juan ^b   Schneider, Robert J ^c   Martínez Montemayor, Michelle M ^a  

^a Universidad Central del Caribe School of Medicine   (Puerto Rico)

^b San Pablo Pathology ^*  (Puerto Rico)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANODERMA LUCIDUM EXTRACT; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BREAST CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; REAL-TIME POLYMERASE CHAIN REACTION; REISHI; TOR SERINE-THREONINE KINASES;

EID: 84874560890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057431     Document Type: Article

References (36)

1. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, et al. (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA: Cancer J Clin 60: 351-375.
2. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, et al. (2006) Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int immunopharmacol 6: 499-508.
3. Lin SB, Li CH, Lee SS, Kan LS, (2003) Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 72: 2381-2390.
4. Lin ZB, (2005) Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci 99: 144-153.
5. Zhu XL, Chen AF, Lin ZB, (2007) Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol 111: 219-226.
6. Sliva D, (2004) Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem 4: 873-879.
7. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, et al. (2002) Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 298: 603-612.
8. Slivova V, Zaloga G, DeMichele SJ, Mukerji P, Huang YS, et al. (2005) Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells. Nutr Cancer 52: 66-73.
9. Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF, (2011) Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer 63: 1085-1094.
10. Cully M, You H, Levine AJ, Mak TW, (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
11. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu M R, et al. (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Can 126: 1121-1131.
12. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
13. Populo H, Lopes JM, Soares P, (2012) The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 13: 1886-1918.
14. Silvera D, Formenti SC, Schneider RJ, (2010) Translational control in cancer. Nat Cell Rev 10: 254-266.
15. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, et al. (2011) mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 31: 2484-2498.
16. Laplante M, Sabatini DM, (2012) mTOR signaling in growth control and disease. Cell 149: 274-293.
17. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, et al. (2009) Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 11: 903-908.
18. Ethier SP, Kokeny KE, Ridings JW, Dilts CA, (1996) erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Cancer Res 56: 899-907.
19. Yuen JW, Gohel MD, Au DW, (2008) Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells. Nutr Cancer 60: 109-119.
20. Martinez-Montemayor MM, Otero-Franqui E, Martinez J, De La Mota-Peynado A, Cubano LA, et al. (2010) Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis 27: 465-480.
21. Castillo-Pichardo L, Martinez-Montemayor MM, Martinez JE, Wall KM, Cubano LA, et al. (2009) Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols. Clin Exp Metastasis 26: 505-516.
22. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ, (2008) eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 181: 293-307.
23. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, et al. (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285: 7866-7879.
24. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864.
25. Dumstorf CA, Konicek BW, McNulty AM, Parsons SH, Furic L, et al. (2010) Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther 9: 3158-3163.
26. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
27. Hernandez-Aya LF, Gonzalez-Angulo AM, (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16: 404-414.
28. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D, (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49: 209-216.
29. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK, (2011) Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta pharmaceutica 61: 335-342.
30. Chen NH, Liu JW, Zhong JJ, (2010) Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacological reports: PR 62: 150-163.
31. Carlson AL, Hoffmeyer MR, Wall KM, Baugher PJ, Richards-Kortum R, et al. (2006) In situ analysis of breast cancer progression in murine models using a macroscopic fluorescence imaging system. Lasers in surgery and medicine 38: 928-938.
32. Lo AC, Georgopoulos A, Kleer CG, Banerjee M, Omar S, et al. (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. Breast 18: 55-59.
33. Fudge K, Bostwick DG, Stearns ME, (1996) Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. The Prostate 29: 282-286.
34. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, et al. (2005) Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer research 65: 9953-9961.
35. Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, et al. (2004) Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circulation research 94: 1186-1194.
36. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG, (2004) Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. The Journal of biological chemistry 279: 1010-1019.